Form 4: Alto Neuroscience's Chief Medical Officer, Adam Savitz, Acquires 76,000 Employee Stock Options

Adam Savitz, Chief Medical Officer of Alto Neuroscience, acquired 76,000 employee stock options on February 5, 2025, according to a Form 4 filing.

Summary

• Adam Savitz, the Chief Medical Officer of Alto Neuroscience, acquired 76,000 employee stock options on February 5, 2025.
• The options have an exercise price of $4.20.
• The options vest over time, with 25% vesting on February 5, 2026, and the remainder vesting monthly until February 4, 2035, contingent upon continuous service.
• Following the transaction, Savitz directly owns 76,000 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects an executive's increased stake in the company, suggesting confidence.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders (officers, directors, or those holding more than 10% of the company's shares) trade in the company's securities. It provides transparency into insider transactions.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in the biotechnology industry.
• The vesting schedule described (25% after one year, then monthly) is fairly standard.
• Comparing the size of the grant to similar companies would require more data on Alto Neuroscience's compensation practices and market capitalization.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a key executive.

Key Dates